tert-butyl 4-(phenylcarbamoyl)piperidine-1-carboxylate | 162881-76-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-(phenylcarbamoyl)piperidine-1-carboxylate
• CAS: 162881-76-7
• 化学式: C₁₇H₂₄N₂O₃
• 分子量: 304.389
• InChiKey: VRRISHHVENWRED-UHFFFAOYSA-N

物化性质

• 熔点：
  140-142 °C
• 沸点：
  477.1±38.0 °C(Predicted)
• 密度：
  1.156±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Phenyl 1-BOC-piperidine-4-carboxamide
Synonyms: tert-Butyl 4-(phenylcarbamoyl)piperidine-1-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Phenyl 1-BOC-piperidine-4-carboxamide
CAS number: 162881-76-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C17H24N2O3
Molecular weight: 304.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(phenylcarbamoyl)piperidine-1-carboxylate 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 反应 12.0h， 生成 N-苯基-4-哌啶羧酰胺盐酸盐
  参考文献：
  名称：

  发现作为有效，可逆和选择性单酰基甘油脂肪酶抑制剂的芳基甲酰基哌啶衍生物。

  摘要：

  当前大多数的单酰基甘油脂肪酶（MAGL）抑制剂通过不可逆的作用机理发挥作用，引起一系列副作用。在此，从不可逆抑制剂开始，合成了25种化合物并进行了体外MAGL抑制评估，其中，化合物36表现出最强的抑制活性（IC 50 = 15 nM）。至关重要的是，对接研究表明，米-氯基取代的苯胺片段占用由Val191，Tyr194，Val270，和Lys273的侧链，其创造性标识新的关键点的锚定为新MAGL抑制剂发展包围的疏水副袋中。此外，体内评估创新地揭示了这种可逆抑制剂36显着改善了利血平引起的抑郁样行为。据我们所知，这是首次开发可逆性MAGL抑制剂来支持MAGL作为抑郁症的潜在治疗靶标。

  DOI：

  10.1021/acs.jmedchem.9b02137
• 作为产物：
  描述：

  苯胺 在 Carbonyldiimidazole 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 为溶剂， 反应 91.0h， 生成 tert-butyl 4-(phenylcarbamoyl)piperidine-1-carboxylate
  参考文献：
  名称：

  DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS

  摘要：

  本公开提供具有药物和生物影响特性的化合物，它们的药物组合物和使用方法。具体而言，该公开涉及具有独特抗病毒活性的二酮哌嗪和哌啶衍生物。更具体地说，本公开涉及用于治疗艾滋病毒和艾滋病的化合物。

  公开号：

  US20070249579A1

文献信息

• [EN] FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS<br/>[FR] INDOLES FONCTIONNALISÉS ET SUBSTITUÉS UTILISÉS EN TANT QU'AGENTS ANTI-CANCÉREUX
  申请人：NOVOGEN LTD

  公开号：WO2015074123A1

  公开（公告）日：2015-05-28

  The present invention relates to anti-tropomyosin compounds, processes for their preparation, and methods for treating or preventing a proliferative disease, preferably cancer, using compounds of the invention.

  本发明涉及抗肌球蛋白化合物，其制备方法，以及利用本发明的化合物治疗或预防增殖性疾病，优选癌症的方法。
• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ANDREWS STEVEN W

  公开号：WO2018071454A1

  公开（公告）日：2018-04-19

  Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供了Formula I的化合物：(I)或其药用可接受的盐或溶剂，其中A、B、X1、X2、X3、X4、环D、E、Ra、Rb、n和m的含义如规范中所述，它们是RET激酶的抑制剂，并且在治疗和预防可以用RET激酶抑制剂治疗的疾病中非常有用，包括与RET相关的疾病和紊乱。
• Amine Activation:<i>N</i>-Arylamino Acid Amide Synthesis from Isothioureas and Amino Acids
  作者：Yan-Ping Zhu、Pieter Mampuys、Sergey Sergeyev、Steven Ballet、Bert U. W. Maes

  DOI：10.1002/adsc.201700134

  日期：2017.7.17

  functional group compatibility, with respect to side chain functionality of the amino acid (e. g. aliphatic and aromatic OH, (hetero)aromatic NH, amide NH, thioether), and the chiral amino acids do not undergo epimerization. The mechanism of the new amide synthesis has been studied.

  Ñ -arylamino酰胺已经通过基于新方法被合成ñ -芳基胺活化成异硫脲，随后用下铁催化氨基酸反应。可以使用三组分反应与市售试剂叔丁基异氰化物和S-苯基苯硫代磺酸盐轻松地制备活化的N-芳基胺。相对于氨基酸（例如脂族和芳族OH，（杂）芳族NH，酰胺NH，硫醚）的侧链官能度，该方案显示出广泛的官能团相容性，并且手性氨基酸不发生差向异构化。已经研究了新酰胺合成的机理。
• 2-aryl indole derivatives and their use as therapeutic agents
  申请人：——

  公开号：US20010039286A1

  公开（公告）日：2001-11-08

  The present invention relates compounds of the formula (I): 1 wherein R 1a , R 1b ; and R 2 represent a variety of substituents; R 3 represents an optionally substituted phenyl, biphenyl or naphthyl or heteroaryl group; R 4 represents hydrogen, C 1-6 alkyl, carbonyl (=O), (CH 2 ) p phenyl or a C 1-2 alkylene bridge across the piperidine ring; R 5 and R 6 each independently represent a variety of substituents; or R 5 and R 6 together are linked so as to form an optionally substituted 5-or 6-membered ring; X represents an oxygen or a sulfur atom, two hydrogen atoms, ═NH or ═N(C 1-6 alkyl); Y is a straight or branched C 1-4 alkylene, C 2-4 alkenylene or C 2-4 alkynylene chain; the dotted line represents an optional double bond; m is zero or an integer from 1 to 4; n is an integer from 1 to 4; and p is an integer from 1 to 4; or a pharmaceutically acceptable salt thereof. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migaine, emesis or postherpetic neuralgia.

  本发明涉及以下式（I）的化合物： 1 其中 R 1a ，R 1b ; 和 R 2 代表各种取代基; R 3 代表可选择地取代的苯基、联苯基或萘基或杂环芳基; R 4 代表氢、C 1-6 烷基、羰基（=O）、（CH 2 ） p 苯基或穿过哌啶环的 C 1-2 烷基桥; R 5 和 R 6 各自独立地代表各种取代基; 或 R 5 和 R 6 一起连接以形成可选择地取代的5-或6-成员环; X代表氧或硫原子、两个氢原子、═NH或═N(C 1-6 烷基); Y是直链或支链C 1-4 烷基、C 2-4 烯基或C 2-4 炔基链; 虚线表示可选的双键; m为零或1至4的整数; n为1至4的整数; p为1至4的整数; 或其药学上可接受的盐。 这些化合物在治疗或预防抑郁症、焦虑、疼痛、炎症、偏头痛、呕吐或带状疱疹后神经痛方面特别有用。
• Amino acid analog CCK antagonists
  申请人：Abbott Laboratories

  公开号：US05346907A1

  公开（公告）日：1994-09-13

  Analogs of CCK-tetrapeptides, which analogs have the formula ##STR1## wherein A, B, D, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are specifically defined, having activity as CCK antagonists, useful in the treatment or prevention of disorders of the gastrointestinal, central nervous, appetite regulating or pain regulating systems.

  CCK-四肽类似物，其分子式为##STR1##其中A、B、D、R.sup.1、R.sup.2、R.sup.3和R.sup.4具体定义，具有作为CCK拮抗剂的活性，在治疗或预防胃肠、中枢神经、食欲调节或疼痛调节系统的紊乱中有用。